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I. INTRODUCTION 
The tensions between policy and practice in returning re-
search results (RRs) and incidental findings (IFs) in genomic 
biobank research are readily apparent and potentially increas-
ing as biobanks are built at a more frenzied pace. As a result, 
more policies are proffered and practices are ever more widely 
varied. Particularly for the Western mind, tension can have 
negative connotations, and in the face of it, one may consider 
reducing or eliminating it as a productive goal. However, ten-
sion is a force of balance, and allowing for a continuum, rather 
than a dichotomous world, is a generative role for tension. As 
the tension between policy and practice increases, it will lead to 
some novel and necessary solutions. In fact, tension can be a 
beacon that highlights the critical issues and even helps deter-
mine both policy and practice—a generative dialogue share-
holders should be part of—as well as what processes will accel-
erate the balance. 
This paper will consider the current tensions between poli-
cy and practice from a number of stakeholders’ perspectives. It 
will also consider future tensions that might arise as data-
sharing in general becomes more of a norm and contributors of 
biological samples and clinical data become more proactively 
engaged in biomedical research.1 
Genomic biobank research means different things to many 
people. Further, the widely varying results coming from these 
biobank systems may lead to varying tensions.2 There are sev-
eral ways to approach this discussion, and for the sake of using 
the various stakeholders as spokespersons for the tensions, we 
will use a fairly simple—somewhat inclusive—model. I will 
consider the biobank to be the entire system as defined by the 
2012 Wolf Consensus Document. Thus, the term biobank refers 
to the system of primary researcher, biobank, and secondary 
researcher.3 
                                                 
 1. See Sharon F. Terry & Patrick F. Terry, Commentary, Power to the 
People: Participant Ownership of Clinical Trial Data, 3 SCI. TRANSLATIONAL 
MED. 69cm3, at 2 (2011). 
 2. See generally Jasper Bovenberg et al., Biobank Research: Reporting 
Results to Individual Participants, 16 EUR. J. HEALTH L. 229 (2009) (discuss-
ing the results of a study on whether and how any results derived from re-
search with large scale biobanks should be communicated to individual re-
search participants). 
 3. Susan M. Wolf et al., Special Article, Managing Incidental Findings 
and Research Results in Genomic Research Involving Biobanks and Archived 
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This does not mean that I will simplify to such an extent as 
to ignore each of these dimensions. In fact, a complex matrix is 
needed to describe the intersection of various continuums. RRs 
and IFs can occur in various contexts from research to clinical 
care to public health (Figure 1). There are many roles in a 
biobank system and only the three delineated by the 2012 Wolf 
Consensus Document would be in a position to return RRs or 
IFs. Findings might be applicable to an individual, a family, a 
community, or to an aggregate population.4 Finally, specific or 
general results can be returned.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Continuum in which RR and IFs occur. 
A. CURRENT POLICIES 
I begin with a cursory review of policies and practices.6 
There are a relatively large number of polices and guidelines 
applicable to the governance of biobanks. In a 2008 review of 
policies, Haga reported fourteen international guidelines for 
biobanks and forty-four national and regional sets of guide-
lines.7 Some of these guidelines impact the return of RRs and 
                                                 
Data Sets, 14 GENETICS MED., 361 (2012). 
 4. See id. at 6–7. 
 5. See id. at 7−8. 
 6. For a more complete discussion, see Wolf et al., supra note 3. 
 7. Susanne B. Haga & Laura M. Beskow, Ethical, Legal, and Social Im-
plications of Biobanks for Genetics Research, 60 ADV GENET 505, 509–11 
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some IFs, but not all address them explicitly.8 In fact, the 2012 
Wolf Consensus Document, in an extensive study, found that 
current biobank policies vary and U.S. biobanks are almost 
evenly divided on whether they address the return of IFs and 
RRs.9 
i.  To Return or Not to Return 
Biobank policies range from returning no results at all to 
returning some results.10 Vanderbilt University Medical Cen-
ter’s BioVU is “one of few biobanks” set up to conduct 
“non-human subjects research” and “the design explicitly pre-
cludes re-contact with any individual.”11 This policy rests on an 
Office for Human Research Protections (OHRP) guidance that 
stated studies with data or samples not collected for the specific 
research in question or not readily identifiable sources will not 
be considered human subjects research.12 
Two recommendations put forth by a working group con-
vened by the National Heart Lung and Blood Institute are also 
relevant as an example of a biobank policy: 
Recommendation 1[:] Individual genetic results should be offered to 
study participants in a timely manner if they meet all of the following 
criteria: 
a. The genetic finding has important health implications for the 
participant, and the associated risks are established and substan-
tial. 
b. The genetic finding is actionable, that is, there are established 
therapeutic or preventive interventions or other available actions 
that have the potential to change the clinical course of the dis-
ease. 
c. The test is analytically valid, and the disclosure plan complies 
with all applicable laws. 
d. During the informed consent process or subsequently, the 
study participant has opted to receive his or her individual genet-
ic results.13 
                                                 
(2008). 
 8. See id. at 508–12. 
 9. Wolf et al., supra note 3, at 365–66. 
 10. Id. 
 11. Jill Pulley et al., Principles of Human Subjects Protections Applied in 
an Opt-Out, De-Identified Biobank, 3 CLINICAL TRANSLATIONAL SCI. 42, 48 
(2010). 
 12. Guidance on Research Involving Coded Private Information or Biologi-
cal Specimens, OFF. HUM. RES. PROTECTIONS (Aug. 10, 2004), 
www.hhs.gov/ohrp/archive/humansubjects/guidance/cdebiol04.htm. 
 13. Richard R. Fabsitz et al., Ethical and Practical Guidelines for Report-
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Recommendation 4[:] Investigators may choose to return individual 
genetic results to study participants if the criteria for an obligation to 
return results are not satisfied (see Recommendation 1) but all of the 
following apply: 
a. The investigator has concluded that the potential benefits of 
disclosure outweigh the risks from the participant’s perspective. 
b. The investigator’s I[nstitutional] R[eview ]B[oard] has ap-
proved the disclosure plan. 
c. The test is analytically valid and the disclosure plan complies 
with all applicable laws. 
d. During the informed consent process or subsequently, the 
study participant has opted to receive his/her individual genetic 
results.14 
ii.  More Recent Policy Recommendations 
After considering these and many other recommendations, 
the recommendation made by the 2012 Wolf Consensus Docu-
ment states what responsibilities biobanks should shoulder: 
(1) clarifying the criteria for evaluating findings (e.g., analytic validi-
ty, seriousness of condition, and actionability) and the roster of re-
turnable IFs and [RRs]; (2) analyzing a particular finding in light of 
those criteria and that roster to determine if it constitutes a returna-
ble IF or [RR]; (3) re-identifying the individual (or individuals) for po-
tential return; and (4) recontacting the individual (or individuals) to 
offer the finding.15 
Certainly these recommendations shift the onus for return-
ing results from the primary researcher, previously the most 
common focus for this responsibility, to the entire biobank re-
search system. The 2012 Wolf Consensus Document defines the 
system as including primary and secondary researchers and 
the biobank.16 This suggests that the system should ensure 
that necessary IFs and RRs are offered to participants, with the 
biobank itself responsible for general oversight. The entire 
biobank system must have a procedure for evaluating findings, 
along with a list of returnable IFs and [RRs], and be responsi-
ble for determining which results are offered to participants.17 
Furthermore, the biobank research system must be able to 
                                                 
ing Genetic Research Results to Study Participants: Updated Guidelines from a 
National Heart, Lung, and Blood Institute Working Group, 3 
CARDIOVASCULAR GENETICS 574, 575 (2010). 
 14. Id. at 577. 
 15. Wolf et al., supra note 3, at 371. 
 16. Id. at 3–4. 
 17. See id. at 9. 
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identify and recontact the donor(s) relevant to the finding.18 IFs 
and RRs with unlikely net benefit for donors should not be re-
turned; however, there should be a distinction made between 
those results biobank systems must return and those that may 
be returned, based on net benefit.19 Donors and potential do-
nors should be involved throughout this process by providing 
input on their preferences regarding returning results, while 
biobanks learn from outcomes, and share experiences with oth-
er biobanks, in order to improve the system.20 
Funders and regulators must also share some of the re-
sponsibility.21 There should be processes for regulators to en-
sure that biobanks follow the standards set down for returning 
results and to support these biobanks in creating and updating 
these standards. The Advanced Notice of Proposed Rule Mak-
ing on the Common Rule (ANPRM) published by the Office of 
Human Research Protections (OHRP) in July 2011 proposes 
that inclusion of a sample in a biobank will require explicit 
consent.22 This proposed new rule arises from concerns that 
many biobanks obtain and archive samples without the partici-
pants’ knowledge and may resolve some of the complexities in-
herent in returning results. If biobanks inform and even engage 
participants during this consent process by educating them 
about having identifying information stored in a way that ena-
bles RR, then many of the tensions dissipate. However, OHRP 
may have inadvertently disincentivized biobanks from engag-
ing participants since the ANPRM indicates that research that 
doesn’t return results is “excused”: a new category that doesn’t 
require the researchers go to an IRB to use the samples.23 
OHRP asked many questions related to this issue in their re-
quest for comments.24 
Funders, be they public or private, must recognize the ad-
ditional burden created by the necessity of having a system for 
returning results and must allocate funding accordingly.25 
                                                 
 18. Id. at 9–10. 
 19. Id. at 13. 
 20. Id. at 19. 
 21. See id. 
 22. Human Subject Research Protections: Enhancing Protections for Re-
search Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 
76 Fed. Reg. 44512, 44515 (July 26, 2011). 
 23. Id. at 44518–19. 
 24. Id. at 44520–21. 
 25. See Wolf et al., supra note 3, at 364. 
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Funders can also require, through a variety of carrot and stick 
mechanisms, return of IFs and RRs. They will not be consid-
ered in this paper as distinct stakeholders, but are active play-
ers in the system and affect the level of tension in the system. 
iii.  International Issues 
Some authors have recommended that it is critical in a 
global age that international policies be considered.26 To some 
extent, the international community has led policy develop-
ment in this regard: 
Indeed, the [incidental findings] issue was acknowledged by the in-
ternational community in the mid-1990s in a statement by the inter-
national Human Genome Organization (HUGO), which declared that 
“choices to be informed or not with regard to results or incidental 
findings should . . . be respected.” In its “International Ethical Guide-
lines for Biomedical Research Involving Human Subjects,” the Coun-
cil for International Organizations of Medical Sciences (CIOMS) has 
provided that “individual subjects will be informed of any finding that 
relates to their particular health status.” CIOMS also states that 
“subjects have the right of access to their data on demand, even if 
these data lack immediate clinical utility.”27 
Zawati et al. argue that Spanish law implies that every 
person has the right to be informed of his or her genetic data 
and other data of a personal nature that are obtained in the 
course of a biomedical research.28 Some of these international 
policies are worded more strongly than U.S. policies.29 Many of 
these policies have their basis in human rights.30 In general, 
U.S. policies present themselves as recommendations to the in-
stitutions holding the samples, rather than describing the 
rights of the participant. 
                                                 
 26. See generally Lynn G. Dressler, Biobanking and Disclosure of Re-
search Results: Addressing the Tension Between Professional Boundaries and 
Moral Intuition, in THE ETHICS OF RESEARCH BIOBANKING 85 (Jan Helge 
Solbakk et al. eds., 2009) (discussing the emerging ethical imperative from in-
ternational guidelines to communicate research results to the individual and 
questioning how that these duties can be implemented in practice). 
 27. Wolf et al., supra note 3, at 367 (citations omitted). 
 28. See Ma’n H. Zawati et al., Incidental Findings in Genomic Research: A 
Review of International Norms, 9 GENEDIT 1, 5 (2011) (“The Spanish Law con-
firms the existence of the participant’s right ‘not to know’ about incidental 
findings.”). 
 29. Wolf et al., supra note 3, at 367. 
 30. See id. at 7–8. 
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B. CURRENT PRACTICES 
There is significant variation, both within the United 
States and abroad, in the practice of how biobanks handle re-
turning IFs and RRs.31 Some biobanks, for instance, offer no re-
sults of any kind to research participants, while others only re-
lease aggregate data.32 
Even within the subset of biobanks offering some form of 
returning IFs and RRs, there is still a wide deviation.33 Certain 
biobanks offer only IFs to participants or only provide particu-
lar individualized RRs, whereas other biobanks consistently of-
fer all IFs and RRs. The Coriell Personalized Medicine Collabo-
rative, for example, is a multi-institutional study in the United 
States that periodically offers both IFs and RRs to research 
participants.34 On the other end of the spectrum is the Iceland-
ic Biobank, launched in 1998, which gave full ownership of 
health information to the state35 and released no results—
aggregate or individual. Most biobanks fall somewhere in the 
middle, like the UK Biobank, which offers IFs found during ini-
tial testing and grants access to the aggregate results, but it 
provides no other IFs or RRs.36 
Thus, policy and practice are tightly coupled in a few in-
stances, but for the most part policies regarding return of RRs 
or IFs have not yet been formulated and practice varies a great 
deal based on the individual researchers involved, the culture 
of the institution and the region, and the level of involvement of 
the participants. 
A project called the Electronic Medical Records and Ge-
nomics Network (eMERGE) is potentially a good place to ex-
plore the tensions between policy and practice. This is a compi-
lation of five major medical center sites, a data coordinating 
center, and National Institutes of Health, using a broad range 
                                                 
 31. Id. 
 32. Id at 5. 
 33. See, e.g., id. at 5–6 (“Among those biobanks that do address [the issue 
of returning IFs and RRs], some return no findings at all, some return non-
genetic IFs (such as abnormal blood pressure) discovered at enrollment, some 
return a subset of non-genetic or genetic IFs, and some return a subset of non-
genetic or genetic [RRs].”). 
 34. Catharine B. Stack et al., Genetic Risk Estimation in the Coriell Per-
sonalized Medicine Collaborative, 13 GENETICS MED. 131, 131 (2011). 
 35. David E. Winickoff, Partnership in U.K. Biobank: A Third Way for Ge-
nomic Property?, 35 J.L., MED. & ETHICS 440, 441 (2007). 
 36. Haga & Beskow, supra note 7, at 533. 
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of community engagement—through surveys and focus 
groups—to assess a priori values and concerns.37 In addition, 
some biobanks are engaging in deliberative democracy within 
the various communities and are also studying population atti-
tudes toward biobanks.38 These sites are involving communities 
in design and oversight and allowing these sites to explore par-
ticipants’ attitudes about policies and practice.39 
C. EMERGENCE OF PARTICIPANT-CENTRIC PERSPECTIVES 
In the midst of these considerations of returning IFs and 
RRs, nonmedical data sharing—with return of results—has be-
come more commonplace. In many areas in life, it is now easy 
to access and share data. Feedback is expected and ubiquitous. 
Consumers experience this in Netflix recommendations, iTunes 
Genius, and Facebook friends’ likes and dislikes. Individuals 
share information and experiences in web applications such as 
Amazon, Angie’s List, MapMyRide, FitBit, Daily Burn, and Ni-
ke and expect results back—how do I stack up against others 
and what do I need to change in my shopping, eating, or 
workout routine? Models are also emerging in clinical data 
sharing with various kinds of feedback and results shared. 
23andMe gives individuals their genome sequence and some 
research results back.40 Individuals can receive dozens of re-
search results via a password-protected web platform.41 Some 
argue that the “23andMe model promotes the idea that curiosi-
ty about one’s genome on the one hand, and participation in re-
search on the other, are not only compatible but complemen-
tary aspects of being an entrepreneurial subject of 
contemporary health and medicine framed by the technologies 
                                                 
 37. See Catherine A McCarty et al., The eMERGE Network: A Consortium 
of Biorepositories Linked to Electronic Medical Records Data for Conducting 
Genomic Studies, 4 BMC MED. GENOMICS 13 (2011) (discussing the general set 
up and efficacy of the eMERGE Network). 
 38. See, e.g., Catherine A. McCarty et al., Community Consultation and 
Communication for a Population-Based DNA Biobank: The Marshfield Clinic 
Personalized Medicine Research Project, 146A AM. J. MED. GENETICS 3026, 
3027–28 (2009). 
 39. Id. 
 40. Thomas Goetz, 23AndMe Will Decode Your DNA for $1,000. Welcome 
to the Age of Genomics, WIRED.COM (Nov. 17, 2007), 
http://www.wired.com/medtech/genetics/magazine/15-12/ff_genomics. 
 41. Id. 
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of web 2.0.”42 The return of these results is not based on clinical 
practice guidelines, instead the ‘results’ are based on correla-
tions being established using common evidentiary standards, 
for example through genome-wide association studies that have 
led to associations with specific conditions.43 
In another participatory web service, PatientsLikeMe col-
lects information about individuals, at their own initiative, on 
hundreds of aspects of their lives.44 This data, in an aggregated 
form, has proven useful to the research enterprise. 
PatientsLikeMe and 23andMe have shown through research 
conducted in their communities that participatory web services 
hold enough power to replicate traditional studies.45 
An individual seeking associations relevant to his or her 
genome can use an add-on for the Firefox browser called 
SNPTips, created by 5 AM | Solutions.46 A person can associate 
their 23andMe genome sequence data with SNPTips and 
webpages that include single-nucleotide polymorphisms 
(SNPs), from news articles to scientific papers, and reveal rele-
vant SNPs.47 This is certainly the tip of the iceberg in ‘network 
effect’ tools—tools that will augment the newly emerging data 
collections. In another example, Private Access gives individu-
                                                 
 42. Richard Tutton & Barbara Prainsack, Enterprising or Altruistic 
Selves? Making Up Research Subjects in Genetics Research, 33 SOC. HEALTH & 
ILLNESS 1081, 1081 (2011). 
 43. See, e.g., Chuong B. Do et al., Web-Based Genome-Wide Association 
Study Identifies Two Novel Loci and Substantial Genetic Component for Par-
kinson’s Disease, 7 PLOS GENETICS, no. 6, 2011, at 1, 2, 
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002141; 
Joyce Y. Tung et al., Efficient Replication of Over 180 Genetic Associations 
with Self-Reported Medical Data, 6 PLOS ONE, no. 8, 2011, at 1, 1–2, 
http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0023473. 
 44. See Paul Wicks et al., Sharing Health Data for Better Outcomes on 
PatientsLikeMe, 12 J. MED. INTERNET RES. e19, e21 (2010) [hereinafter Shar-
ing Health Data] (“PatientsLikeMe is a Web-based application where members 
explicitly choose to share detailed computable data about symptoms, treat-
ments and health in order to learn from the experience of others and improve 
their outcomes.”). 
 45. See, e.g., Nicholas Eriksson et al., Web-Based, Particpant-Driven Stud-
ies Yield Novel Genetic Associations for Common Traits, 6 PLOS GENETICS, no. 
6, 2010, at 1, 1–2, http://www.plosgenetics.org/article/info:doi/ 
10.1371/journal.pgen.1000993; Sharing Health Data, supra note 44, at e19–
e20; Paul Wicks et al., Accelerated Clinical Discovery Using Self-Reported Pa-
tient Data Collected Online and a Patient-Matching Algorithm, 29 NATURE 
BIOTECH. 411, 411–12 (2011) [hereinafter Accelerated Clinical Discovery]. 
 46. SNPTIPS, http://snptips.5amsolutions.com/ (last visited Feb. 8, 2012). 
 47. See id. 
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als a platform to enter their preferences for how their data will 
be handled, including who can see it, how it can be used, and 
what should be returned to the individual.48 It provides tech-
nology solutions for researchers to communicate with partici-
pants in trials—including results and incidental finding report-
ing—all according to the individual’s preferences. The 
individuals themselves, not the scientists, determine what is 
shared and what is returned.49 Genomera, a small Silicon Val-
ley company, provides a unique platform for individuals to 
share genomic and phenotypic information. It is unique be-
cause it allows individuals to set up the trials, and they are 
aided by the tools the company provides to run and analyze the 
trial.50 This system allows on-the-fly return of results, either on 
an individual or a group level. None of these examples are tra-
ditional return of results or incidental findings. But all of them 
point to a growing trend for consumers to expect results—
something that may very well carry over into the biomedical 
research arena. 
D. RETURN OF RRS AND IFS IN GENOMICS BIOBANKS: 
SOMETHING DIFFERENT THAN NON-GENOMIC STUDIES? 
There has been much discussion about “genetic 
exceptionalism” over the years. This discussion has vacillated 
between the premise that there is nothing different about ge-
netic or genomic information and the idea that it is different 
and requires different handling, guidance, regulations, and so 
on.51 With respect to RRs, some studies show that individuals 
do consider genetic information to be different than other medi-
cal information, either because it reveals more information 
about health risks or because it may have meaning for the par-
ticipant’s family.52 While familial importance can be implicated 
                                                 
 48. Robert H. Shelton, Commentary, Electronic Consent Channels: Pre-
serving Patient Privacy Without Handcuffing Researchers, 3 SCI. 
TRANSLATIONAL MED. 69cm4, at 2 (2011). 
 49. Id. 
 50. See Ella Dolgin, Personalized Investigation, 16 NATURE MED. 953, 954 
(2010); Terry & Terry, supra note 1, at 2. 
 51. Michael J. Green & Jeffrey R. Botkin, “Genetic Exceptionalism” in 
Medicine: Clarifying the Differences Between Genetic and Nongenetic Tests, 
138 ANNALS INTERNAL MED. 571, 571 (2003). 
 52. See Miguel Ruiz-Canela et al., What Research Participants Want to 
Know About Genetic Research Results: The Impact of “Genetic Exceptionalism,” 
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in any data associated with indication of familial disease, it is 
especially obvious in genetic data.53 Green and Botkin exam-
ined genetic exceptionalism and found “no clear, significant dis-
tinctions between genetic and nongenetic tests justify[ing] a 
different approach to testing by clinicians. Nevertheless, with 
many genetic tests, the results may cause stigmatization, fami-
ly discord, and psychological distress.”54 
It is true that genetic information may have consequences 
for the family, and genomic biobank policies should guide in-
formation exchange—even for the relatives of a contributor and 
even after the death of that contributor.55 Vos et al. examined 
the impact on individuals who were told the results about un-
classified variants and uninformative BRCA 1 & 2 testing for 
family members.56 The way results were communicated was 
significant to family members’ perception of their own cancer 
risk.57 Thus, despite some mixed evidence and conclusions, it is 
probably safe to say that genetic information at least gives in-
dividuals, families, and communities pause, and hence causes 
other stakeholders to at least ask if special considerations ap-
ply. For the sake of this paper we will restrict comments to IFs 
and RRs in genomic biobanks, but realize that many of these 
issues are inherent in IFs and RRs in non-genomic research as 
well. 
E. THE RELATIVITY OF TIME AND CONTEXT 
Differences between IFs and RRs are not always clear. For 
example, Bovenberg et al. use the term RR to encompass IFs.58 
They include results to individuals as well as aggregate re-
sults.59 Others are more careful as to the specificity of the 
terms as is clearly laid out by Wolf et al.60 
                                                 
6 J. EMPIRICAL RES. ON HUM. RES. ETHICS 39, 40 (2011). 
 53. See Laura M. Beskow et al., Ethical Issues in Identifying and Recruit-
ing Participants for Familial Genetic Research, 130A AM. J. MED. GENETICS 
424, 425 (2004) (explaining the importance of family-based research in a varie-
ty of diseases). 
 54. Green & Botkin, supra note 51, at 571. 
 55. Bovenberg et al., supra note 2, at 240. 
 56. Joël Vos et al., Family Communication Matters: The Impact of Telling 
Relatives About Unclassified Variants and Uninformative DNA-Test Results, 
13 GENETICS MED. 333, 333 (2011). 
 57. Id. at 339. 
 58. Bovenberg et al., supra note 2, at 230. 
 59. Id. 
 60. Wolf et al., supra note 3, at 364. 
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Wolf et al.’s research discovered that many biobanks, stud-
ies, and policies recognize a difference between IFs and indi-
vidual RRs.61 For example, Yale University’s institutional re-
view boards (IRBs) have established policies recognizing that, 
in some studies, IFs may be returned but not individuals’ 
RRs.62 The UK Biobank is time dependent and will offer some 
IFs discovered during enrollment (such as elevated blood pres-
sure) to participants but will not offer individual RRs from the 
ensuing genetic/genomic analysis. However, once into the re-
search, the UK biobank does not provide individual RR for any 
reason.63 
Wolf et al. acknowledge that “[s]ome commentators have 
questioned the utility of distinguishing between IFs and [RRs], 
especially in the context of whole-exome, whole-genome, or ge-
nome-wide association studies (GWAS)” and agrees that the 
distinction is “fuzziest” in these domains.64 Whole-genome se-
quencing in clinics provides us an excellent example of the 
blurring of research and clinical settings and the distinction be-
tween what is an IF and what is an RR. As more systems like 
this are built to ascertain correlations in a hypothesis-
generating environment, the differences between RR and IF 
will continue to blur. The term biobank will refer to the system 
and the stakeholders in it; the terms IF and RR will be used to 
describe a range of findings in keeping with Wolf’s definition. 
Typically, results are considered RRs, and not clinical re-
sults that should be disclosed to participants, because of a lack 
of evidence of clinical utility.65 Over time, with the aggregation 
                                                 
 61. Id. 
 62. Id. 
 63. Id. at 4–5. 
 64. Id. at 4; see also Laura M. Beskow & Wylie Burke, Commentary, Of-
fering Individual Genetic Research Results: Context Matters, 38 SCI. 
TRANSLATIONAL MED. 38cm20, 2 (2010) (explaining that the distinction be-
tween RRs and IFs based on “whether the information is related to the study” 
is problematic because “[e]ven when the initial study addresses a particular 
condition, consent is often requested to store materials for use in unspecified 
future research”); Mildred K. Cho, Understanding Incidental Findings in the 
Context of Genetics and Genomics, 36 J.L. MED. & ETHICS 280, 281−82 (2008) 
(noting that distinguishing IFs from other findings is difficult “because the na-
ture of the genomic research question can be very open ended or descriptive”). 
 65. Susan M. Wolf et al., Managing Incidental Findings in Human Sub-
jects Research: Analysis and Recommendations, 36 J. L. MED. & ETHICS 219, 
231−32 (2008) [hereinafter Wolf, Analysis and Recommendations]. 
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of increasingly large datasets correlated with clinical infor-
mation, RRs either become useful clinical results or become ir-
relevant because they are proven to be insubstantial.66 The in-
creasingly grey line between research and clinical care means 
that it is not always possible to determine if something is an 
RR or in fact has clinical attributes. Thus something may be an 
RR today, and as data is aggregated and analyzed, it may be-
come more meaningful over time. This makes it difficult to cre-
ate a definitive line before which to determine something is an 
RR, and after which something is a clinical result. The infor-
mation itself can be independent of the system in which it was 
obtained, though some would point out that a result cannot be 
a clinical result unless it is obtained in a laboratory that is cer-
tified by the Clinical Laboratory Improvement Amendments 
(CLIA).67 The issue then is one of appropriate infrastructure to 
deliver these results. 
IFs may be considered such only because they were not the 
intent of the study. They can be considered incidental findings 
in one context and primary findings in another. Again, the sys-
tem in which they are discovered may not allow contextualiza-
tion to play a role, nor provide the infrastructure to deliver the 
results. But the results themselves are not the issue. In both 
RRs and IFs, what participants believe to be reportable and 
what is considered as having clinical utility may be different. 
We address this below. 
Context and time play a significant role that is difficult to 
manage in the strict research context in the integration of ge-
nomics into clinical care. When systems exist that allow re-
search and clinical care to cohabitate (as in some emerging pro-
grams in research universities collaborating with their health 
centers), and information to be aggregated, correlated, and ana-
lyzed in real time—in the way that Amazon provides consumer 
feedback or TripAdvisor shares restaurant ratings and com-
ments—then the issues that arise as a result of returning RRs 
and IFs will be less onerous. 
Even when genomic biobanks establish, ahead of any re-
cruiting, a roster of findings that will be reported back, this 
should be considered a starting point since ongoing research 
will continue to find associations in various populations and for 
some individuals. Further, though such advisory boards are 
                                                 
 66. See id. at 232−33. 
 67. See id. at 230. 
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recommended and useful, they cannot always determine what 
will be important to individuals in reproduction, life, death, or 
personal decisions.68 
In addition to the meaning of various results changing over 
time due to research advances, personal preferences can change 
throughout the life course due to many circumstances.69 Needs 
change for individuals depending on their personal and familial 
circumstances.70 Reproductive planning, healthcare interac-
tions, the diagnosis of oneself or someone in the family, deaths, 
and media reports about genetics, genomics and disease, are 
among the issues that could alter preferences as to receive re-
search results and incidental findings. 
Another aspect of context is related to culture. There are 
cultures in which biobanking represents an objectification of 
the community, an exploitation of the tribe, or simply part of 
something unthinkable, such as the removal, storage, and ex-
perimentation on blood or tissue.71 
A final contextual aspect is the right not to know. Even 
when a biobank has decided certain results are important to 
share, an individual may not want to know about the result.72 
Though some would say that this right be exercised as long as 
it does not cause harm.73 Not suprisingly, recent studies show 
that individuals fall in a contiuum of wanting to know, not 
wanting to know, and many in the middle want results at least 
when they are accurate and actionable.74 
                                                 
 68. Wolf et al., supra note 3, at 370. 
 69. Robert Klitzman, Questions, Complexities, and Limitations in Disclos-
ing Individual Genetic Research, AM. J. BIOETHICS, Nov.−Dec. 2006, at 34, 34–
35; see also Constance A. Griffin et al., Patient Preferences Regarding Recon-
tact by Cancer Genetics Clinicians, 6 FAMILIAL CANCER 265, 269 (2007) (find-
ing that patients wanted to be recontacted with new information regarding a 
genetic test for various reasons including information regarding cancer risk to 
the patient and relatives, cancer screening, and impacts on the patients’ 
health). 
 70. Id., at 35. 
 71. See, e.g., Michelle M. Mello & Leslie E. Wolf, The Havasupai Indian 
Tribe Case—Lessons for Research Involving Stored Biologic Samples, 363 NEW 
ENG. J. MED. 204, 204 (2010) (explaining that tribe members objected to use of 
their blood samples for various cultural reasons). 
 72. See Rebecca Bennett, Antenatal Genetic Testing and the Right to Re-
main in Ignorance, 22 THEORETICAL MED. & BIOETHICS 461, 462 (2001). 
 73. Id. 
 74. Bovenberg et al., supra note 2, at 232–33. 
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II. TENSION FOR WHOM? 
The tension in the system must be considered from numer-
ous viewpoints since any tension is the result of several forces. 
These forces will be applied and perceived differently by vari-
ous stakeholders. Thus, it is not possible to name tensions be-
tween practice and policy without examining those from the 
perspective of each stakeholder. The key stakeholders, though 
there are certainly others, are individual participants, commu-
nities, researchers, clinicians, institutions, and society. I write 
with a strong bias that all research be participant-centered, 
and will therefore call the donors, patients, and contributors of 
clinical data and/or samples, participants. 
A.  PARTICIPANTS 
The primary tensions for participants between current pol-
icies and practices can be described as arising from expecta-
tions, literacy, support, usefulness, and fears. 
i. Expectations 
When participants enter into a relationship with a genomic 
biobank system, they will have expectations.75 In ethics consid-
erations, “expectations are not just neutral facts.”76 They indi-
cate obligations on other individuals or entities to consider 
them.77 This might suggest that participants consider the in-
teraction with the biobank to be relational, rather than trans-
actional. I do believe this is the case, given the desire of partic-
ipants to trust the biobank system and to expect reciprocity 
from the whole and its parts.78 
Participants’ expectations vary. Certainly the time and 
context issues raised above will color expectations. Thus some 
participants will expect results, and others will be indifferent. A 
fairly large, and increasing, body of research suggests that par-
ticipants expect to receive some RRs back. For example, in one 
Dutch study, between 70% and 88% of what the researchers 
called “patients” and “citizens” “probably” or “definitely” want-
ed results to be communicated to them, dependent on the type 
                                                 
 75. Id. at 233. 
 76. Id. at 238. 
 77. Id. 
 78. Herbert Gottweis et al., Connecting the Public with Biobank Research: 
Reciprocity Matters, 12 NATURE REVS. GENETICS 738, 739 (2011). 
009 TERRY_PROOF -SK.DOCX (DO NOT DELETE) 7/5/2012 1:21 PM 
708 MINN. J. L. SCI. & TECH. [Vol. 13:2 
 
 
of results. 79 In this study, questionnaires were given to indi-
viduals with asthma, hay fever, or thrombosis (called patients) 
and to healthy volunteers (called citizens). Citizens preferred 
being informed of research results slightly more than pa-
tients.80 
Although it sometimes appears that privacy concerns, and 
hence how a biobank manages the samples and data they ac-
quire, are most critical when considering whether or not to con-
tribute to a biobank, one study found willingness to contribute 
tied to the presence of a binding agreement between the parties 
including the return of results.81 Focus group participants in 
this study conducted by the Genetics and Public Policy Center 
expressed an overwhelming desire for a “contract” with re-
searchers.82 This suggests that the public thinks there should 
be reciprocity between researchers and participants.83 Indica-
tive of the diversity in preferences, in the Dutch study refer-
enced above, some participants did not want to be informed of 
results.84 
As potential participants become increasingly involved and 
empowered in health and other aspects of their lives, there may 
be expectations that both policies and practices will be consum-
er focused.85 These participants may expect that the research 
enterprise is there to benefit them, and they may not expect ei-
ther a one-size-fits-all system or one that does not return any 
results. Participants may be surprised to find that the research 
enterprise doesn’t have a culture of sharing information either 
between projects or with participants.86 Participants may ex-
pect clear and well-articulated policies that serve the partici-
pant.87 Some of the confusion in expectations may relate to an 
understanding of what is research and what is clinical care. 
Though there is certainly an element of literacy in this aspect, 
                                                 
 79. Bovenberg et al., supra note 2, at 233. 
 80. Id. 
 81. Juli Murphy et al., Public Perspectives on Informed Consent for 
Biobanking, 99 AM. J. PUB. HEALTH 2128, 2132−33 (2009). 
 82. Id. 
 83. Id. 
 84. Bovenberg et al., supra note 2, at 232. 
 85. See Amy Dockser Marcus, Citizen Scientists, WALL ST. J., Dec. 3, 2011, 
at C.1. 
 86. See id. 
 87. See, e.g., Murphy et al., supra note 81, at 2132–33. 
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it is also probable that many biobank systems do not make the 
distinction clear in policy and practice. There is a tacit trust 
that the participant is being cared for, particularly in rare dis-
ease research.88 And finally, some participants do not want re-
searchers to have results that they themselves do not have.89 
ii. Literacy 
Participant literacy, or lack thereof, causes a great deal of 
tension in the system. A biobank can have well-articulated pol-
icies, and then when it implements those policies it may find 
that the participants cannot comprehend the policy and/or the 
results as the biobank intended. In some genetic testing, partic-
ipants are educated as to the range of possible findings before 
disclosure.90 A number of studies have shown that participants 
can lack comprehension of the study in which they are partici-
pating.91 Genetic literacy is based on health literacy, which, in 
turn, is built on science literacy.92 A 1993 study, repeated with 
the same results in 2002, showed that forty-seven percent of 
U.S. adults “lack the literacy skills needed to meet the de-
mands of twenty-first century society” defined as having “diffi-
culty locating, matching, and integrating information in writ-
ten texts with accuracy and consistency.”93 Obviously, if 
individuals find it difficult to understand information, then 
RRs and IFs will also be difficult to understand. 
iii. Usefulness 
Usefulness from the participant perspective differs from 
the technical definition of clinical utility, which is discussed be-
low in Part II.C. Usefulness simply asks: is this information 
useful? For the participant, the answer to that is not a clinical 
answer—it takes into consideration all of the issues of time and 
                                                 
 88. Henry S. Richardson & Leah Belsky, The Ancillary-Care Responsibili-
ties of Medical Researchers, 34 HASTINGS CTR. REP. 25, 27 (2004). 
 89. David Wendler & Rebecca Pentz, How Does the Collection of Genetic 
Test Results Affect Research Participants?, 143A AM. J. MED. GENETICS 1733, 
1736 (2007). 
 90. See Ellen Wright Clayton, Incidental Findings in Genetic Research 
Using Archived DNA, 36 J.L. MED. & ETHICS 286, 289 (2008). 
 91. E.g., Mary Dixon-Woods et al., Beyond “Misunderstanding”: Written 
Information and Decisions About Taking Part in a Genetic Epidemiology 
Study, 65 SOC. SCI. & MED. 2212, 2219 (2007). 
 92. See INST. OF THE NAT’L ACAD., HEALTH LITERACY: A PRESCRIPTION TO 
END CONFUSION 146 (Lynn Nielsen-Bohlman et al. eds., 2004). 
 93. Id. at 6. 
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context described in Part I.E above. Generally, participants 
consider: (1) how is this information relevant to me, (2) how do 
I act on it, and (3) who or what will support me through the ac-
tionable steps? Beyond clinical utility, usefulness denotes re-
sults that can be meaningful for families and individuals and 
communities. These can be related to family lineage, ethnic or 
cultural identity, and behavioral traits that could define per-
sonal identity for the individual.94 
Botkin et al. describe a tension in the system when they 
consider that systematic evaluation is a challenge for tradition-
al methods of evidence-based review when considering the 
broader impact of genetic tests on the individual, familial and 
societal levels, and psychosocial outcomes.95 He describes the 
need to consider potential harms and benefits for the partici-
pant and the challenge of doing that in the Centers for Disease 
Control and Prevention initiated program called Evaluation of 
Genomic Applications in Practice and Prevention (EGAPP), 
which evaluates genetic tests.96 The issues inherent in individ-
ual preferences, and a growing understanding that information 
impacts reproductive decision making,97 offspring,98 and even-
tually other uses, have garnered some attention and are con-
sidered by some authors.99 Called “personal utility,” peer re-
viewed literature is beginning to highlight this participant-
centric appraisal of genetic tests.100 Several efforts to reconcile 
these tensions have been offered in the form of categorizing 
tests, using either a matrix that considers a test’s risk-benefit 
                                                 
 94. Vardit Ravitsky & Benjamin S. Wilfond, Disclosing Individual Genetic 
Results to Research Participants, AM. J. BIOETHICS, Nov.−Dec. 2006, at 8, 12. 
 95. Jeffrey R. Botkin et al., Outcomes of Interest in Evidence-Based Eval-
uations of Genetic Testing, 12 GENETICS MED. 228, 228 (2010). 
 96. Id. at 229−30. 
 97. Fabsitz et al., supra note 14, at 578; Wolf, Analysis and Recommenda-
tions, supra note 68, at 231. 
 98. See Susanne B. Haga & Sharon F. Terry, Ensuring the Safe Use of 
Genomic Medicine in Children, 48 CLINICAL PEDIATRICS 703, 703−05 (2009). 
 99. See, e.g., Conrad V. Fernandez & Charles Weijer, Obligations in Offer-
ing to Disclose Genetic Research Results, AM. J. BIOETHICS, Nov.−Dec. 2006, at 
44, 45–46 (arguing for a broader participant-focused definition of utility). 
 100. See, e.g., Scott D. Grosse et al., Evaluation of the Validity and Utility 
of Genetic Testing for Rare Diseases, in RARE DISEASES EPIDEMIOLOGY 115, 
121–27 (Manuel Posada de la Paz & Stephen C. Groft eds., 2010); Ilona M. 
Kopitz et al., Willingness to Pay for Genetic Testing for Alzheimer’s Disease: A 
Measure of Personal Utility, 15 GENETIC TESTING & MOLECULAR BIOMARKERS 
871, 871 (2011). 
009 TERRY_PROOF -SK.DOCX (DO NOT DELETE) 7/5/2012 1:21 PM 
2012]  TENSION BETWEEN POLICY AND PRACTICE 711 
profile against its clinical uncertainty,101 or investigating which 
IF’s specialists would recommend returning,102 or using a for-
mal risk-benefit framework for genomic tests that could take 
context into consideration.103 A three-tier system has been rec-
ommended: Tier 1 “Implement in practice;” Tier 2a “Informed 
decision-making in practice;” and Tiers 2b and 3 “Do not use in 
practice” (for different reasons).104 Though this doesn’t take 
personal utility into consideration, it does begin to provide a 
basis for more complex decision making than just yay or nay. 
This may begin to resolve the tension in ‘usefulness’. This sys-
tem, combined with one that gives weight to the preferences of 
participants in the context of their lived experience and a vehi-
cle for them to express their preferences, would provide a dy-
namic solution to the intersection of clinical and personal utili-
ty. 
iv. Support 
A critical tension in the system is support for participants 
as they receive, or do not receive, IFs and RRs. This is often 
considered from the clinicians’ or the institutions’ point of view. 
Discussions about the need for a larger workforce, licensure for 
genetic counselors, and/or cost to interpret genomic infor-
mation—with no clear payment system for information shar-
ing—are common.105 It appears less common to consider this 
from the participant perspective. The lack of integration be-
tween research and clinical systems creates a gap in which the 
participant can fall as they try to navigate information. The 
support that participants need in learning of IFs and RRs is 
highly variable. Some studies have shown that how information 
                                                 
 101. See, e.g., David L. Veenstra et al., A Formal Risk-Benefit Framework 
for Genomic Tests: Facilitating the Appropriate Translation of Genomics into 
Clinical Practice, 12 GENETICS MED. 686, 691 (2010). 
 102. See Robert C. Green et al., Exploring Concordance and Discordance 
for Return of Incidental Findings from Clinical Sequencing, 14 GENETICS 
MED. 405, 406 (2012). 
 103. See, e.g., Muin J. Khoury et al., Evidence-Based Classification of Rec-
ommendations on Use of Genomic Test in Clinical Practice: Dealing with Insuf-
ficient Evidence, 12 GENETICS MED. 680, 682 (2010). 
 104. Id. 
 105. See, e.g., Wolf, Analysis and Recommendations, supra note 68, at 243 
(“Research would be helpful to clarify the types of IFs generated by different 
kinds of research, the statistical prevalence of these IFs, the costs of evaluat-
ing them and clinical following-up, and the positive and negative impacts on 
research participants.”). 
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is delivered and by whom is critical.106 Some individuals will 
need written materials, some verbal communications, and oth-
ers general community support with multimedia reinforcement. 
Particularly as the evidence develops for various findings, par-
ticipants are going to need dynamic methods to stay apprised of 
the meaning of these findings and how they are relevant or not 
to their lives, for example, Private Access, 23andMe, and 
PatientsLikeMe.107 This is like being given a very slowly devel-
oping Polaroid photograph and keeping it for years, watching 
more of the image appear over time. As information becomes 
more available, and more or less meaningful, the need for effec-
tive support for interpretation, application, and overall man-
agement of that information will change. This is a very chal-
lenging aspect of RRs and IFs for participants. 
v. Fears 
1. Discrimination 
Individuals could fear discrimination in employment or in-
surance, even though the Genetic Information Nondiscrimina-
tion Act of 2008 (GINA)108 defends the rights of individuals in 
the United States in this regard, and comparable laws do this 
in other countries.109 Individuals certainly could face discrimi-
nation in areas not covered by the law such as long-term care 
and disability insurance.110 In one study, individuals who were 
worried that study results would be used against them were 
less inclined to participate in a hypothetical large-population 
study.111 There is a need for further education about GINA for 
participants and providers if fear of discrimination is to be alle-
viated.112 
                                                 
 106. Johanna L. Schmidt et al., The Impact of False-Positive Newborn 
Screening Results on Families, 14 GENETICS MED. 76, 77–78 (2012). 
 107. See Terry & Terry, supra note 1, at 2. 
 108. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-
233, 122 Stat. 881 (codified in scattered sections of 26, 29, and 42 U.S.C.). 
 109. Amy L. McGuire & Mary Anderlik Majumder, Two Cheers for GINA?, 
1 GENOME MED. 6.1, 6.1–6.2 (2009), http://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC2651591/pdf/gm6.pdf. 
 110. Id. at 6.2. 
 111. David J. Kaufman et al, Public Opinion about the Importance of Pri-
vacy in Biobank Research, 85 AM. GENETICS 643, 647–48 (2009). 
 112. Amanda L. Laedtke et al., Family Physicians’ Awareness and 
Knowledge of the Genetic Information Non-Discrimination Act (GINA), J. 
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2. Lack of Care 
A related tension in the system is related to the fact that 
there will not only be little information for some IFs and RRs, 
but many times these findings are not actionable. Findings 
might predict a condition, convey risk, diagnose a condition, 
and so on, but across the board, there is a high chance that 
there is no treatment based on these findings. Even in the case 
of ending the diagnostic odyssey, it has been reported that in-
dividuals suffer a loss of confidence in the medical care sys-
tem.113 In an examination of expanded newborn screening in 
California, incidental findings related to diagnosing the mother 
appear to leave the family unsatisfied if the family is unable to 
act on the information. This may be because the newborn 
screening infrastructure is not set up to support treatment for 
the mother.114 
3. Anxiety Associated with Risk 
Early in the personal genomics movement, ethicists con-
sidered whether individuals would have increased anxiety as a 
result of genetic information and hypothesized that they 
might.115 In recent years, some studies suggest that there is 
less anxiety over receiving results than previously thought, 
though most studies were based on cohorts that availed them-
selves of counseling.116 Other studies emphasize that the differ-
ences in perceptions are based upon the level of counseling 
available to the individuals.117 There is a need for more re-
                                                 
GENETIC COUNSELING (forthcoming 2012) (e-pub at 7), available at 
http://www.springerlink.com/content/r35524617242351l/fulltext.pdf; McGuire 
& Majumder, supra note 109, at 6.2. 
 113. Milica Markovic et al., Embodied Changes and the Search for Gyneco-
logical Cancer Diagnosis, 18 MED. ANTHROPOLOGY Q. 376, 387 (2004). 
 114. Mara Buchbinder & Stefan Timmermans, Newborn Screening and 
Maternal Diagnosis: Rethinking Family Benefit, 73 SOC. SCI. & MED. 1014, 
1017 (2011). 
 115. Amy McGuire et al., The Future of Personal Genomics, 317 SCIENCE 
1687, 1687 (2007). 
 116. Katja Aktan-Collan et al., Psychological Consequences of Predictive 
Genetic Testing for Hereditary Non-polyposis Colorectal Cancer (HNPCC): A 
Prospective Follow-up Study, 93 INT. J. CANCER 608, 611 (2001); Chanita 
Hughes Halbert et al., Long-Term Reactions to Genetic Testing for BRCA1 and 
BRCA2 Mutations: Does Time Heal Women’s Concerns?, 29 J. CLINICAL 
ONCOLOGY 4302, 4305–06 (2011); Kay Wilhelm et al., Issues Concerning Feed-
back About Genetic Testing and Risk of Depression, 194 BRIT. J. PSYCHIATRY 
404, 409 (2009). 
 117. Sato Ashida et al., The Role of Disease Perceptions and Results Shar-
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search in this area, particularly since there are no studies ex-
amining the psychological effects of RR and IF for individuals 
who did not chose to be tested. Meanwhile, disparities may be 
exacerbated as individuals who can afford testing, and perhaps 
unnecessary follow up tests, may ‘raid the medical commons.’118 
This impacts communities, which is described in the next sec-
tion. 
B. COMMUNITIES 
The tension between policy and practice for communities is 
difficult to quantify and even difficult to describe succinctly. 
There appear to be a number of questions that need to be asked 
in this regard, and no ready answers. 
i. How Do IFs and RRs Challenge Community Identity or 
Norms? 
One must ask if the IFs create some conflict in worldview 
vis-à-vis the community or if the identity of the community is 
challenged by the RRs or IFs? One can imagine that incidental 
findings or research results that are common to the community 
could challenge the community’s sense of who it is. This could 
be true in an ethnic or geographic community as well as dis-
ease-based community. While most of the literature on this 
subject is about ancestry, there are also some indications that 
having a predisposition to a disease may also threaten a com-
munity’s understanding of themselves.119 Blogs and other post-
ings from adolescents with cystic fibrosis (CF) indicate that 
‘disease legends,’ akin to urban legends, may arise. For exam-
ple, some in the CF community have created associations be-
tween mutations and classes of severity that do not reflect the 
                                                 
ing in Psychological Adaptation After Genetic Susceptibility Testing: The 
REVEAL Study, 18 EUR. J. HUM. GENETICS 1296, 1300 (2010). 
 118. Amy L. McGuire & Wylie Burke, An Unwelcome Side Effect of Direct-
to-Consumer Personal Genome Testing: Raiding the Medical Commons, 300 
JAMA 2669, 2669–70 (2008). 
 119. Dena S. Davis, Genetic Research & Communal Narratives, 34 
HASTINGS CENTER REP. 40, 42 (2004); Carl Elliot & Paul Brodwin, Identity 
and Genetic Ancestry Tracing, 325 BRIT. MED. J. 1469, 1471 (2002); Susan 
Parry & Carl Elliot, Genetic Ancestry Tracing and American Indian Identity, 
AM. PHIL. ASS’N NEWSL. ON PHIL. & MED., Spring 2002, at 12; Mee Lian Wong 
et al., Concerns over Participation in Genetic Research Among Malay-Muslims, 
Chinese and Indians in Singapore: A Focus Group Study, 7 COMMUNITY 
GENETICS 44, 45 (2004). 
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currently scientifically validated correlations. Anecdotes in the 
community abound trying to use these unfounded correlations 
to modulate behavior: “Can I ask ? Is there certain C[F] genes 
that are more sever [sic] than others or does it make any differ-
ence?”120 This is an area that can use further research. If 
groups of people (cities, neighborhoods, affinity groups online, 
and church communities) are given IFs and RRs, will they 
build their own consensus around the results, determining be-
havior, and making recommendations? I certainly see individu-
als beginning to build their own conclusions, without scientific 
evidence, in the online Facebook community and in the Chat 
listserv I manage for PXE International, which serves the ge-
netic disease pseudoxanthoma elasticum (PXE). One post on 
Facebook follows up many claims that fish oil is a good treat-
ment for PXE, which is a disease caused by mutations in 
ABCC6—a gene that codes for a membrane transport protein. 
The Facebook user posted: 
I havent tried [fish oil], but i am getting some tomorrow. Yes Karen, I 
am always in pain, my hip joints and knees, They are worse in the 
cold. If I walk for a long time too. My gp said my right kneecap is 
moving inward and will need an op eventually !!! I am sure it is pxe 
related. I also get leg pain all ove,r claudication, i dont like taking 
pills so use the ibuprofen gel when it is at its worse xxxx I also get 
sore wrists.121 
There is no evidence of joint involvement in PXE122 and 
certainly no research on fish oil that suggests it would alleviate 
any symptoms in the condition. However, the group makes its 
own determinations of such matters through reading a small 
number of posts from individuals. Even when we repeatedly 
point them to layman versions of peer-reviewed published lit-
erature, some group members chastise us for not allowing them 
to ‘learn from one another.’ This could create a set of communi-
                                                 
 120. Ronnie Sharpe & Mandi Sharpe, RUN, SICKBOY, RUN (June 1, 2011), 
http://runsickboyrun.blogspot.com/2011/06/question-from-reader-more-severe-
genes.html. 
 121. Karen McDougall & Maria Taggart, PXE International Group, 
FACEBOOK (Dec. 11, 2011, 12:52 PM), 
https://www.facebook.com/groups/6236484169/ (errors in the original). 
 122. Nat’l Ass’n for Pseudoxanthoma Elasticum, Frequently Asked Ques-
tions - Pain, PXENAPE, http://www.pxenape.org/faq.htm (last visited Feb. 28, 
2012) (responding to the question of whether a person’s joint aches and pains 
are a result of PXE, “[A]rthritic symptoms of any kind are not directly related 
to or caused by PXE. Mild to moderate joint aches and pains are very common 
among the general population . . . [, and] it cannot be said that the cause is 
PXE”). 
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ty beliefs. While the group members are not basing their 
treatments on specific mutations, one can imagine that the 
same groupthink would be applied to mutations discovered in 
PXE International research projects123 if they were distributed 
to the group. 
ii. Increased Data Sharing and Comparison Through 
Technology 
The above examples lead to other questions about the dif-
ference between policy and practice in communities. Primarily 
one must ask if the sharing of results in online communities 
will create fodder for network effect systems to create ecosys-
tems—i.e., can communities create their own data capture and 
share and reveal associations beyond what the original re-
search intended? This has been shown to be the case in the 
PatientsLikeMe community and to some extent in 23andMe cli-
ents. In the PatientsLikeMe community, individuals reported 
changes in their behavior based on shared information.124 This 
will create other tensions, such as what to do when the practice 
of sharing results leads to altered behavior not part of clinical 
practice guidelines. There are certainly pros and cons to this 
effect. 
iii. Obligation to Share IFs and RRs that Are Meaningful for 
the Community 
Policies about IFs and RRs usually refer to individuals. In 
some cases, those results might have meaning for the broader 
community, and perhaps should be shared proactively with the 
community, possibly in a generalized way. For example, found-
er effects, increased environmental risk, and strong correla-
tions in a particular genotype would all be candidates for broad 
dissemination. A number of researchers recommend engaging 
the community in question to help determine return of results 
policies.125 
                                                 
 123. See, e.g. Ellen G. Pfendner et al., Mutation Detection in the ABCC6 
Gene and Genotype-Phenotype Analysis in a Large International Case Series 
Affected by Pseudoxanthoma Elasticum, 44 J. MED. GENETICS 621 passim 
(2007). 
 124. See Accelerated Clinical Discovery, supra note 46, at 413. 
 125. See, e.g., Lainie Friedman Ross et al., Human Subjects Protections in 
Community Engaged Research: A Research Ethics Framework, 5 J. EMPIRICAL 
RES. HUM. RES. ETHICS 5, 7 (2010); Richard R. Sharp & Morris W. Foster, 
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iv. Vulnerable Communities 
1. Power Differential When Information Is Not Uniformly 
Available to All Parties 
The local control of data access may be important to a 
community, and this may be difficult if the advisory body is 
removed from the community—as is done in some cases—
particularly in large communities such as countries, cities, or 
even large university medical centers.126 Further, RR can be 
seen as a necessary demonstration of respect and reciprocity for 
the community. 
2. Potential Discrimination If RRs or IFs in a Group Are 
Aggregated 
One could imagine that if a SNP purported to be associated 
with violence is highly prevalent in a cohort and research re-
sults are reported back to a community, that the community 
could suffer from aggregate results even if the association lacks 
validation. Communities could find results inconsistent with 
their beliefs and myths or fear stigmatism as has been reported 
by a number of authors.127 Some communities have a difficult 
experience during the research process and then choose not to 
participate thus limiting the promise of translational medi-
cine.128 This has pros and cons for the community in question—
                                                 
Grappling with Groups: Protecting Collective Interests in Biomedical Research, 
32 J. MED. & PHIL. 321, 325 (2007). 
 126. See Fabsitz et al., supra note 14, at 577. 
 127. See, e.g., Ibidapo Akinleye et al., Differences Between African Ameri-
can and White Research Volunteers in Their Attitudes, Beliefs and Knowledge 
Regarding Genetic Testing for Alzheimer’s Disease, 20 J. GENETIC 
COUNSELING. 650, 656 (2011); Henry T. Greely, Informed Consent and Other 
Ethical Issues in Human Population Genetics, 35 ANN. REV. GENETICS 785, 
798 (2001); Evaristus A. Nwulia et al., Ethnic Disparities in the Perception of 
Ethical Risks from Psychiatric Genetic Studies, 156 AM. J. MED. GENETICS 
PART B 569, 578 (2011); LorrieAnn Santos, Genetic Research in Native Com-
munities, 2 PROGRESS COMMUNITY HEALTH PARTNERSHIPS 321, 322–23 (2008) 
(describing the objections of the Havasupai Indian tribe after blood samples 
taken from members of the tribe were used in a study of schizophrenia, which 
the Tribe felt risked stigmatization, and “inbreeding,” which implicated nega-
tive cultural beliefs). 
 128. See generally Ellen Wright Clayton & Lainie Friedman Ross, Implica-
tions of Disclosing Individual Results of Clinical Research, 295 JAMA 37, 37 
(2006) (explaining that “respect for research participants requires minimizing 
harms so that they are not treated as mere means for scientific ends”); Steph-
anie M. Fullerton et al., Commentary, Meeting the Governance Challenges of 
Next-Generation Biorepository Research, 2 SCI. TRANSLATIONAL MED. 15cm3, 
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they will benefit from retaining power over their information 
and samples, but their community may be denied the benefits 
of research that may lead to diagnostics and therapies, particu-
larly when those are community specific. In vulnerable com-
munities, offering RRs and IFs could encourage a ‘therapeutic 
misconception’— the belief a clinical trial is primarily for ther-
apeutic reasons.129 
C. RESEARCHERS 
There are some who have written that showing respect to 
participants doesn’t necessarily mean giving back results.130 
Researchers must concern themselves with analytic validity, 
clinical validity, and clinical utility.131 It is beyond the scope of 
this paper to discuss the current state of evidence generation to 
determine thresholds for each of these steps on the way to inte-
gration into clinical practice. As mentioned above, EGAPP and 
other efforts are trying to create a formal risk-benefit frame-
work. It is thought that such a framework could offer guide-
lines for meaningful integration of genomic applications and 
avoid premature use of tests with little benefit or health signif-
icance.132 
The tension in policy and practice is sometimes quite high 
for researchers, particularly those that receive samples that 
have been de-identified. This is in fact research that is not cov-
                                                 
at 3 (2010) (noting that “[r]esearch participants often cite a fear of having 
their genetic or personal health information used against them should it fall 
into the wrong hands”); Michelle M. Mello & Leslie E. Wolf, The Havasupai 
Indian Tribe Case – Lessons for Research Involving Stored Biologic Samples, 
363 NEW ENG. J. MED. 204, 204–05 (reporting a legal settlement between the 
Havasupai Indian Tribe and Arizona State University after blood samples 
taken from members of the tribe by the University were used in studies that 
the tribe felt violated the scope of their consent); Santos, supra note 127, at 
322–23 (describing two specific examples of abuse in genetic research of specif-
ic communities, one involving the Havasupai Indians and another multiple 
instances of abusive practices involving native Hawaiins). 
 129. Cho, supra note 67, at 284. 
 130. Clayton & Ross, supra note 128, at 37; Pilar N. Ossorio, Letting the 
Gene Out of the Bottle: A Comment on Returning Individual Research Results 
to Participants, AM. J. BIOETHICS, Nov.−Dec. 2006, at 24, 24. 
 131. Grosse et al., supra note 100, at 116–21. 
 132. David L. Veenstra et al., A Formal Risk-Benefit Framework for Ge-
nomic Tests: Facilitating the Appropriate Translation of Genomics into Clini-
cal Practice, 12 GENETICS MED. 686, 691–92 (2010). 
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ered by the Common Rule.133 For example, if policy dictates the 
return of IFs and RRs, then the researcher is in an untenable 
position with a difficult pathway to accessing enough infor-
mation to comply with the policy. The Common Rule places 
secondary researchers, those using de-identified data or sam-
ples, outside of the biobank process, and Wolf et al. note that 
many biobanks exist for this purpose.134 
Some researchers may well want to be part of the biobank 
system and wish to return results, and may in fact have an an-
cillary obligation toward participants. Others may enjoy the 
‘absolution’ that consenting participants imply with agreeing to 
the typical terms of no return of research results.135 Research-
ers, while in a gray area of interaction with participants, unlike 
clinicians, do not take a Hippocratic Oath and have no formal 
clinical professional codes of conduct.136 In the Dutch study, as 
reported above, recall that the citizens and patients wished to 
receive findings eighty-five and seventy percent of the time re-
spectively, and ninety-five percent of researchers disagreed 
with returning findings.137 It is probable that researchers were 
not trained in genomic interpretation, nor did they anticipate 
the genomic era in which the line between research and clinical 
services would be so blurred. Some argue that withholding clin-
ically important findings may be paternalistic on the part of re-
searchers.138 It is clearly best for both sides to be aware of the 
others expectations. 
There are a number of considerations for researchers in the 
balance between policy and practice. 
                                                 
 133. HHS Common Rule, 45 C.F.R. § 46 (2011). 
 134. Wolf et al., supra note 3, at 364. 
 135. See generally Bartha Maria Knoppers et al., The Emergence of an Eth-
ical Duty to Disclose Genetic Research Results: International Perspectives, 14 
EUR. J. HUM. GENETICS 1170, 1174 (2006) (“[G]enetic information derived 
from research is of unknown or uncertain predictive value. Therefore, special 
care must be taken to prevent inadvertent release of immature data.”). 
 136. Dressler, supra note 24, at 87. 
 137. Bovenberg et al., supra note 2, at 232. 
 138. See Laura M. Beskow et al., Informed Consent for Population-Based 
Research Involving Genetics, 286 JAMA 2315, 2316 (2001); Conrad Fernandez, 
Public Expectations for Return of Results—Time to Stop Being Paternalistic?, 8 
AM. J. BIOETHICS, no. 11, 2008, at 46, 48; Isaac S. Kohane et al., 
Reestabilishing the Researcher-Patient Compact, 316 SCIENCE 836, 836 (2007). 
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i. Balancing Benefit and Risk: How to Assess and from What 
Perspective? 
As discussed above, the participant has a very different 
perspective from the researcher, whose primary goal is to do 
excellent science. In a climate of evolving technology, data ag-
gregation, and societal interest in genetic information, it is dif-
ficult to determine the weight of benefits and risks. Partici-
pants have expectations, and these may not align with each 
other or with the researchers conducting the study. Vehicles for 
community engagement, coupled with mechanisms for partici-
pants to express their RR and IF preferences, would begin to 
create a new model for resolving this tension. Rather than re-
ject the current paradigm, citizen scientists and those encour-
aging participants to have robust agency in the research enter-
prise, are advocating for a participant-centric system.139 In this 
system, the participants’ and researchers’ needs and obliga-
tions are in dialogue with one another. One example of a sys-
tem that will help participants have more power at least in one 
direction—enabling their data to be used beyond the initial pro-
ject for which it has been collected—is the Portable Legal Con-
sent140 created by Sage Bionetworks, Creative Commons, 
Kaufman Foundation, Genetic Alliance, and other collabora-
tors.141 This falls short of providing participants mechanisms 
for deciding how their data should be used and what should be 
returned to them, as is essential in participant-centric re-
search.142 
                                                 
 139. See Jane Kaye, The Tension Between Data Sharing and the Protection 
of Privacy in Genomics Research, 13 ANN. REV. GENOMICS & HUMAN 
GENETICS (forthcoming 2012) (manuscript at page 13) (advocating that re-
searchers “consider new ways of engaging with research participans . . . [t]o do 
so respects the dignity of participants and protects fundamental human 
rights). 
 140. Draft Informed Consent Form, CONSENT TO RES., 
http://weconsent.us/consentform (last visited April 10, 2012). 
 141. See Your Data Are Not a Product, 44 NATURE GENETICS 357, 357 
(“[R]esearch participants can contribute their own data under a portable con-
sent . . . [f]rom there, the de-identified data can be accessed by any researcher 
who agreed to protect the research subjects and their data under the terms of 
the consent.”). 
 142. See Jane Kaye et al., From Patients to Partners: Participant-Centric 
Initiatives in Biomedical Research, 13 NATURE REV. GENETICS (forthcoming 
2012). 
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ii. Returning Findings Are Time and Resource Intensive: How 
to Pay for Such Activities? 
It can be quite costly on many levels to disclose results, 
and some are concerned that those resources of time and money 
should be used for the research enterprise.143 However, others 
simply ask the question of how it will be weighed in the as-
sessments that need to be done both in creating policies and in 
determining practice.144 Once the decision to return results has 
been made, the logistics of recontacting is not trivial in the cur-
rent systems. If, as is thought by some, participants decide they 
want results returned, then systems will have to be built that 
will allow such preferences.145 In addition, if there is a ‘right 
not to know,’ then these systems must allow sufficiently com-
plex preferences and also allow them to change over time. It is 
not even easy to contact individuals with preliminary IF results 
that require verification, since that in itself reveals some result 
that may require genetic counseling or other follow-up.146 Fur-
ther follow-up for these individuals may burden the health care 
system with requests for diagnostic procedures that lack a 
sound basis.147 Individuals with different levels of literacy will 
require different levels of support, which will require varying 
methods of education and a sundry of follow-up activities. It 
will be easy for individuals who do not have the right kind of 
support and follow-up to ‘raid the medical commons.’ 
iii. Misconceptions Are Easy to Come by: How Can We Address 
Them to Allay Concerns? 
There is a concern articulated by many authors that partic-
ipants could suffer from ‘therapeutic misconception’ and re-
searchers might be inclined to overstate the benefits of enroll-
ment.148 Are the researchers confused as well, or at least 
                                                 
 143. Paul Affleck, Is It Ethical to Deny Genetic Research Participants Indi-
vidualised Results?, 35 J. MED. ETHICS 209, 212 (2009); Griffin et al., supra 
note 69, at 270. 
 144. See Fabsitz et al., supra note 13, at 577. 
 145. Affleck, supra note 143, at 212. 
 146. Cho, supra note 67, at 284. 
 147. Bovenberg et al., supra note 2, at 232. 
 148. Laura M. Beskow, Considering the Nature of Individual Research Re-
sults, AM. J. BIOETHICS, Nov.−Dec. 2006, at 38, 38 (2006); Clayton & Ross, su-
pra note 128, at 37; Fernandez, supra note 138, at 47; Bartha Maria Knoppers 
& Claude Laberge, Return of “Accurate” and “Actionable” Results: Yes!, 9 AM. 
J. BIOETHICS, June–July 2009, at 107, 108; Ossorio, supra note 130, at 25. 
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perhaps lack the ability to communicate results to the partici-
pants?149 It is not usually the activity of researchers to com-
municate results, and so miscommunication is highly proba-
ble.150 
iv. Communicating with Participants Can Be Quite 
Complicated: How Can We Do This? 
Clinicians can fall back on a defined relationship complete 
with a code of conduct, but researchers do not have this luxury. 
There is usually not an obvious or ready set of mores for this 
interaction. What if the participants require ancillary care—
care beyond that required to carry out the research safely—how 
can this be done in a meaningful and utilitarian manner?151 
Though the relationship between researchers and participants 
is not meant to be therapeutic, or clinical,152 one can ask of re-
searchers: If they thought that there was no health benefit, 
then why subject the individuals to the research in the first 
place? Thus, even researchers may be entering into a compact 
with participants that, though not traditionally considered bi-
lateral, are a priori also in a relational interest to the partici-
pant. 
D. CLINICIANS 
Clinicians, like researchers, are in the middle of the ten-
sion between policy and practice, since they will be among 
those who must administer the policy while following formal 
and informal practice guidelines. The clinician may raise sev-
eral issues from his or her perspective. 
                                                 
 149. See Fiona A. Miller et al., When Research Seems Like Clinical Care: A 
Qualitative Study of the Communication of Individual Cancer Genetic Re-
search Results, 9 BMC MED. ETHICS 1, 2 (2008), available at 
http://www.biomedcentral.com/content/pdf/1472-6939-9-4.pdf. 
 150. Lynn G. Dressler & Eric T. Juengst, Thresholds and Boundaries in the 
Disclosure of Individual Genetic Research Results, AM. J. BIOETHICS, 
Nov.−Dec. 2006, at 18, 19. 
 151. Henry S. Richardson, Incidental Findings and Ancillary-Care Obliga-
tions, 36 J.L. MED. & ETHICS 256, 268 (2008). 
 152. Teri A. Manolio, Taking Our Obligations to Research Participants Se-
riously: Disclosing Individual Results of Genetic Research, AM. J. BIOETHICS, 
Nov.−Dec. 2006, at 32, 33. 
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i. I Lack the Resources to Educate the Participant 
Clinicians may well ask: If I don’t understand (or agree 
with) the implications of the finding myself, how will I describe 
it to my patients? Clinicians are challenged in interpreting ge-
netic tests, which are becoming increasingly available through 
both clinical practice settings and through direct-to-consumer 
marketing.153 Though they are becoming more ubiquitous, more 
often than not their clinical utility (for the clinician) or useful-
ness (for the participant) is not evident. Individuals troll the 
web and bring stacks of printed material from websites to office 
visits with clinicians, and clinicians are usually not as familiar 
with this material to even determine its appropriateness.154 
Adding the reporting of RRs and IFs to these challenges will 
create additional burden for clinicians. Clinicians will also be 
faced with either conflicting, or at least nuanced, policies for is-
sues related to results for minors, which will have implications 
for other family members and the potential need for follow-up 
counseling. 
ii. I Have X Minutes per Visit. How Am I Going to Find Time to 
Deal with This? 
With the burden of enormous numbers of tests becoming 
available, as well as the potential to be required to share RRs 
and IFs, already time-crunched clinicians will not be able to 
find the time to advise patients or participants. The current 
medical reimbursement system, particularly in the United 
States, does not generally pay for information exchange or 
counseling. 
iii. This Is My Patient, but I Have to Share Him/Her with a 
Researcher. How Do I Navigate This Complex Relationship? 
If a biobank participant is recruited into a biobank by their 
clinician, and a researcher is using the data and samples, then 
there will be a complex set of relationships for the clinician to 
navigate. Deciding what should be reported, though potentially 
determined by policy at local institutions and the biobank, will 
be complex in practice. Determining how to report the findings 
and what to do about follow-up will require coordination that 
may not be present in the currently available infrastructure or 
                                                 
 153. Joshua L. Deignan & Wayne W. Grody, Ordering Genetic Tests and 
Interpreting the Results, 70 ADVANCES OTO-RHINO-LARYNGOLGY 18, 18 (2011). 
 154. Botkin et al., supra note 95, at 228–29. 
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protocols between clinicians and researchers. Some have sug-
gested that these relationships can be sorted out effectively, for 
example, by allowing others in the team, not the principal re-
searcher, give results to participants.155 
E. INSTITUTIONS 
When institutions put policies into practice the infrastruc-
tures’ needs and necessary protocols may be onerous and/or 
costly. Kohane et al. recommend an electronic system that will 
take into account preapproved ‘returnable findings’ and partic-
ipant preferences.156 Most institutions require human interfac-
es, usually with genetic counselors. For example, the ClinSeq 
project at the National Human Genome Research Institute 
(NHGRI) uses healthcare professionals to report information 
back to participants when such information fits criteria they 
have determined for disease-causing variants.157 Others have 
debated what and when to reveal to patients. The Coriell Per-
sonalized Medicine Cooperative returns findings to individuals, 
differentiating risk on genetic and non-genetic factors.158 The 
REVEAL Study, which focused on reporting apoliprotein E 
(APOE)159 status to individuals, studied the psychological is-
sues related to risk for Alzheimer’s disease and the effects of 
results being reported to individuals.160 
Institutions will need to consider how to conduct informed 
consent in a way that allows compliance with policies that re-
quire RRs and IFs to be returned. Wolf et al. recommend that 
biobanks (and therefore the institutions or organizations that 
determine policy for them) take several steps to assist in this 
process: 
                                                 
 155. Fernandez, supra note 138, at 47. 
 156. Kohane et al., supra note 138, at 836. 
 157. Leslie G. Biesecker et al., The ClinSeq Project: Piloting Large-Scale 
Genome Sequencing for Research in Genomic Medicine, 19 GENOME RES. 1665, 
1671 (2009) (“ClinSeq is a pilot project to investigate the use of whole-genome 
sequencing as a tool for clinical research.”). 
 158. Stack et al., supra note 34, at 134 (“[C]onsented participants provide 
saliva samples, which are genotyped . . . . Using a secure web-based portal, the 
CPMC provides participants with . . . personalized results for potentially ac-
tionable health conditions.”). 
 159. APOE is a susceptibility gene linked with Alzheimer’s Disease. Ashida 
et al., supra note 117, at 1296–97. 
 160. Id. at 1297. 
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[B]iobanks should make sure that primary researchers (or collection 
sites) specify how they plan to handle the issue of IFs and [RRs], and 
indicate that they have consulted their IRB in erecting this plan. 
Biobanks will need to establish an agreement with primary research-
ers (or collection sites) on the respective roles the biobank and prima-
ry research (or collection site) will play in the CARR process. Together 
they will need to consider whether key codes will be housed not just 
at the primary research (or collecting) institution but also at the 
biobank or trusted intermediary . . . .161 
Implementing this process will be easier for biobanks being 
built from the ground up than for those already in existence.162 
It may be difficult for institutions to set institution-wide 
principles, particularly since different departments may view 
both the process of sharing RRs and IFs and the specific deter-
minations of what is shared in different ways depending on 
their sensitivity to the information, sophistication about genetic 
and genomic information, culture of the disciplines they repre-
sent, and sensitivity to the vulnerabilities of their populations 
and/or clients.163 
It will be important to educate the institutional review 
boards (IRBs) associated with the institution. A recent study 
showed that IRBs find oversight challenging as the terrain be-
comes more complex.164 At the very least these entities need to 
consider whether results are from CLIA certified laboratories, 
since some research results are certainly not performed in the-
se labs.165 If not performed in an appropriate lab, the findings 
will need to be validated in a CLIA lab, and the institution will 
probably incur costs for this further testing.166 
In 1999, the National Bioethics Advisory Commission 
(NBAC) put forth some recommendations on the subject: 
IRBs should develop general guidelines for the disclosure of the re-
sults of research to subjects and require investigators to address the-
                                                 
 161. Wolf et al., supra note 3, at 379. 
 162. See Terry & Terry, supra note 1, at 1–2 (noting that there are several 
problems with the old system). 
 163. See generally Ashida et al., supra note 117, at 1299 (noting that re-
porting genetic problems can affect health). 
 164. Amy A. Lemke et al., Broad Data Sharing in Genetic Research: Views 
of Institutional Review Board Professionals, 33 IRB: ETHICS & HUM. RES. 1, 4 
(2011). 
 165. See James O. Westgard, Charts of Operational Process Specifications 
(“OPSpecs Charts”) for Assessing the Precision, Accuracy, and Quality Control 
Needed to Satisfy Proficiency Testing Performance Criteria, 38 CLINICAL 
CHEM. 1226, 1226 (1992) (“These CLIA PT criteria describe limits for the ‘total 
error’ ascribable to the imprecision and inaccuracy of the testing process.”). 
 166. See Wolf et al., supra note 3, at 371. 
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se issues explicitly in their research plans. In general, these guide-
lines should reflect the presumption that the disclosure of research 
results to subjects represents an exceptional circumstance. Such dis-
closure should occur only when all of the following apply: 
a) the findings are scientifically valid and confirmed, b) the 
findings have significant implications for the subject’s health con-
cerns, and c) a course of action to ameliorate or treat these con-
cerns is readily available . . . . When research results are dis-
closed to a subject, appropriate medical advice or referral should 
be provided.167 In 1999, these were appropriate guidelines for 
IRBs. I am not sure that in the past twelve years, IRBs have cre-
ated the policies that were needed—in some ways these recom-
mendations were very forward looking. The second sentence, 
however, belies the age in which these were written—they state 
that going forward, disclosing research results will be “an excep-
tional circumstance.”168 Were these written today, they would be 
more direct and specific; particularly because the quality and rel-
evance of the data generated by whole genome sequencing, which 
is now a much more common occurrence, requires clear disclosure 
policies.169 
Perhaps the greatest tension for institutions will come 
from engaging participants as true participants in the process. 
Institutions and their IRBs—which are created to focus on pro-
tecting research participants—are not built on a relationship-
based engagement model.170 In my work on biobanks for both 
single diseases and multiple diseases, I have built a relational-
trust model in which the biobank is steward for the partici-
pants in which the actual community owns and manages the 
biobank.171 David E. Winickoff suggests that this is indicative 
                                                 
 167. NAT’L BIOETHICS ADVISORY COMM’N, RESEARCH INVOLVING HUMAN 
BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE vi−vii (2000), 
available at http://bioethics.georgetown.edu/nbac/hbm_exec.pdf. 
 168. Id. 
 169. Jane Kaye et al., Ethical Implications of the Use of Whole Genome 
Methods in Medical Research, 18 EUR. J. HUM. GENETICS 398, 402 (2010). 
 170. See Lemke et al., supra note 164, at 1 (outlining the IRB role of in-
forming patients). 
 171. Sharon F. Terry et al., Advocacy Groups as Research Organizations: 
The PXE International Example, 8 NATURE REVS. GENETICS 157, 160 (2007) 
(noting the successes in information gathering and research of such 
partnerships); Sharon F. Terry & Charles D. Boyd, Researching the Biology of 
PXE: Partnering in the Process, 106 AM. J. MED. GENETICS 177, 180–81 (2001) 
(describing the formation and new model of a genetic disease organization); cf. 
David C. Landy et al., How Disease Advocacy Organizations Participate in 
Clinical Research: A Survey of Genetic Organizations, 14 GENETICS MED. 
(forthcoming 2012) (e-pub at 4–5) (discussing the potential pressures to 
participate that can stem from such organizations). 
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of a shift from benefit sharing, common in the biobanks created 
by research institutions, to power sharing: 
[L]ooking at the situation prior to donation and the transfer of enti-
tlement, the group of donors as a collective possesses a crucial form of 
material, informational and biological capital that could be used to 
demand a share of power. This is one of the insights to be drawn from 
the PXE International story, where disease group members formed 
and retained legal control of a biobank in order to help advance the 
particular research goals of the organization.172 
Though the focus of this paper is not this paradigm shift, I 
believe it has implications for institutions that engage in 
biobanking. The idea that the individuals donating samples 
and data to biobanks might share in the power creates new 
mechanisms for decision making about what results are re-
turned, how they are returned, and when they are returned.173 
This shift, since it will be part of what institutions need to con-
sider, will be challenging, particularly for academic medical 
centers, which historically have tended toward a hierarchy that 
does not lend itself to such robust community engagement or 
participant-centered research.174 
F. SOCIETY 
There is some debate about whether biobanks serve society 
or serve the research community more.175 If, in fact, they serve 
society, then society should have a role in the policy setting and 
execution of practice in RRs and IFs. There is no simple mech-
anism to increase participation, but the discussion about litera-
cy above is relevant here for society as well. The engagement of 
society in biobanking in general could increase public interest 
in biomedical research, increase public literacy, and create 
                                                 
 172. David E. Winickoff, From Benefit Sharing to Power Sharing: 
Partnership Governance in Population Genomics Research 13 (Oct. 3, 2008) 
(working paper) (on file with Ctr. for the Study of L. & Soc’y Jurisprudence & 
Soc. Pol’y Program), available at http://escholarship.org/uc/item/845393hh#. 
 173. See Terry et al., Advocacy, supra note 171, at 160 (“The coordination of 
research by PXE International allowed the continued aggregation of both neg-
ative and positive findings, and dissemination of those results.”). 
 174. Kieran C. O’Doherty et al., From Consent to Institutions: Designing 
Adaptive Governance for Genomic Biobanks. 73 SOC. SCI. MED. 367, 367–68 
(2011). 
 175. See Susan M.C. Gibbons et al., Lessons from European Population 
Genetic Databases: Comparing the Law in Estonia, Iceland, Sweden and the 
United Kingdom, 12 EUR. J. HEALTH L. 103, 122 (2005) (noting the distinct 
interests of informing participants and sharing research with the scientific 
community). 
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more active involvement overall.176 
Questions about public health are inherent in societal per-
spectives on returning RRs and IFs because “[t]he central mor-
al concern of public health ethics is to specify the conditions 
that warrant paternalistic interventions that override individ-
ual autonomy to prevent people from adopting unhealthy be-
haviors.”177 
If society becomes more literate, more engaged, and has a 
role in determining the return of RRs and IFs reporting, then 
we must also consider what else might change.178 For example, 
would the relatively paternalistic relationship of researchers 
and patients become more equal?179 If participants feel more 
engaged in the research enterprise, would some of the power 
differential be reduced?180 It is important to consider what 
would become of the clinical trial compact if society and com-
munities were more involved in decision-making about re-
search. Already, some of the social networking sites have al-
tered the clinical trial compact.181 Individuals can share 
information about the trial, potential treatments, and the pros 
and cons of placebos in such a way that trials are not truly 
blind, or worse, they are hard to recruit for.182 Several years 
ago, when antiangiogenesis therapies for macular hemorrhag-
ing became available for common condition macular degenera-
tion, PXE International wanted to do a trial of the new therapy 
against the existing laser therapy. It was impossible to enroll in 
                                                 
 176. Richard R. Sharp & Morris W. Foster, Clinical Utility and Full 
Disclosure of Genetic Results to Research Participants, AM. J. BIOETHICS, 
Nov.−Dec. 2006, at 42, 43. 
 177. M. Sutrop, Viewpoint: How to Avoid a Dichotomy Between Autonomy 
and Beneficence: From Liberalism to Communitarianism and Beyond, 269 J. 
INTERNAL MED. 375, 375 (2011). 
 178. See Sharp & Foster, supra note 176, at 43. 
 179. See Terry & Boyd, supra note 171, at 179 (discussing an anecdote 
where researchers took a sample without an informed consent procedure). 
 180. See generally Sharp & Foster, supra note 176, at 43–44 (explaining 
that informing patients can empower them to make better choices for their 
health). 
 181. See Accelerated Clinical Discovery, supra note 45, at 411–12 (detailing 
research of drug effectiveness through the use of an online forum and a spe-
cialized control matching algorithm). 
 182. See generally A.D. Farmer et al., Social Networking Sites: A Novel 
Portal for Communication, 85 POSTGRADUATE MED. J. 455, 456–58 (2008) (dis-
cussing the sharing that occurs on social networks between people suffering 
from the same disease). 
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such a trial because, using mechanisms PXE International had 
built for community sharing, individuals experiencing hemor-
rhaging went to their retinologists and requested 
antiangiogenesis treatments. There were no participants left 
for a clinical trial. This could become more widespread, and the 
way clinical trials are conducted might have to be restruc-
tured.183 
With the emergence of new technologies comes something 
termed “network effect.”184 As the number of people who partic-
ipate in technology increases, the benefit increases.185 As par-
ticipation increases, changes also occur in the industries, tech-
nologies, and communities around the new technology.186 A 
veritable ecosystem of independent solutions and improve-
ments on the original arise.187 For returning RRs and IFs, it 
will be easier to offer society a role as new technologies arise. 
We have witnessed similar increases in participation in 
numerous other “long tails” in other previously hierarchical in-
dustries.188 Individuals share information via websites and 
apps such as Craigslist, Angie’s List, Amazon, Facebook, and 
iTunes, revolutionizing how consumers have interacted with 
markets and each other. 189 The Arab uprising was certainly 
                                                 
 183. See Accelerated Clinical Discovery, supra note 45, at 412 (describing 
one way that researchers conducted a clinical trial when presented with a 
community that was already participating in a treatment). 
 184. Garth Saloner & Andrea Shepard, Adoption of Technologies with Net-
work Effects: An Empirical Examination of the Adoption of Automated Teller 
Machines, 26 RAND J. ECON. 479, 479–80 (1995). 
 185. Id. at 480 (“[A]s the number of people who make and receive calls in-
creases, each individual can communicate with more people . . . . [E]ach new 
user confers a benefit on all other users.”). 
 186. See Michael L. Katz & Carl Shapiro, Network Externalities, Competi-
tion, and Compatibility, 75 AM. ECON. REV. 424, 425 (1985) (noting that firms 
can make a choice about how to compliment the network effect). 
 187. See Venkatesh Shankar & Barry L. Bayus, Network Effects and Com-
petition: An Empirical Analysis of the Home Video Game Industry, 24 
STRATEGIC MGMT. J. 375, 376 (2003) (noting that there is still competition to 
improve and innovate in network effect markets). 
 188. See The Economist Online, Blockbuster Files for Bankruptcy: From 
Blockbuster to Turkey, ECONOMIST (Sept. 23, 2010), 
http://www.economist.com/blogs/newsbook/2010/09/blockbuster_files_bankrupt
cy/print (discussing how Blockbuster was pushed out in part due to the success 
of Netflix). 
 189. See John Seely Brown & Richard P. Adler, Minds on Fire: Open Edu-
cation, the Long Tail, and Learning 2.0, EDUCASE REV. Jan.–Feb. 2008, at 
17, 26–27 (noting that the internet offers an opportunity to change education 
by uniting people with interests in narrow disciplines). 
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aided by Twitter; traditional power structures cannot with-
stand the power of people.190 Consider the example of Waze, a 
smartphone app that has the tagline “Outsmarting Traffic, To-
gether.”191 It allows travelers to input police presence, radar, 
disabled cars, traffic, and other notable activities along one’s 
travel route, thus giving other users warning about what to ex-
pect—even speed traps!192 As noted above, crowdsourcing medi-
cal information with resources like 23andMe, Private Access, 
PatientsLikeMe, Genomera, and Althea’s Crowd Sourced Lon-
gitudinal Studies have the potential to change the paradigm of 
participation in biomedical research. 
III. CONCLUSION 
A. POTENTIAL SOLUTIONS FOR KEY CHALLENGES 
The tensions between policy and practice for biobanks RRs 
and IFs must, and can be, alleviated to some degree. The goal, 
as mentioned in the introduction, is not to exacerbate these 
tensions but instead to understand them from the perspectives 
of a variety of stakeholders in a variety of contexts.193 Once un-
derstood, the applicable systems can be optimized to increase 
overall health and advance biomedical research. If the entire 
enterprise was built on a relational model rather than a trans-
actional one, many of the disconnects would either be relieved 
or workable in the context of evolving relationships.194 “[T]he 
lack of personal contact (visual, verbal, or otherwise) with a 
participant does not diminish the participant’s stake in the re-
sults or the researcher’s responsibility to consider the value of 
the research finding could have for the research participant.”195 
Certainly some of the processes must be codified protocols that 
                                                 
 190. Peter Beaumont, The Truth about Twitter, Facebook and the Uprising 
in the Arab World, GUARDIAN (Feb. 24, 2011), 
http://www.guardian.co.uk/world/2011/feb/25/twitter-facebook-uprisings-arab-
libya (noting that social media had varying but important effects in the revolu-
tions across the Arab world). 
 191. WAZE, http://www.waze.com/ (last visited Feb. 9, 2012). 
 192. About Us, WAZE, http://www.waze.com/about/about_us/ (last visited 
Feb. 9, 2012). 
 193. See supra Figure 1. 
 194. See Sharp & Foster, supra note 176, at 43. 
 195. Lynn G. Dressler & Eric T. Juengst, Thresholds and Boundaries in the 
Disclosure of Individual Genetic Research Results, AM. J. BIOETHICS, Nov.–
Dec. 2006, at 18, 18–19. 
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are immutable, and all processes must be based in carefully 
thought out policies; however, the execution of these policies 
and procedures should be relationally based. This has been said 
quite well by Lynn G. Dressler: 
DNA and other human specimen banking coupled with studies in ge-
netic and genomic research highlight the need to transition to a more 
socially responsible standard of research conduct in biomedicine. We 
need a deliberative process to address the roles and responsibilities of 
biobankers and researchers to inform the development of “codes of 
conduct.” This process must address the tensions between moral intu-
ition and professional boundaries so the resulting codes are broad 
enough to allow for moral analysis and yet narrow enough to provide 
some boundary for decision-making. This would require moving to-
ward a collaborative process for decision-making, with a strong in-
volvement by the community and contributors to the biobank, not just 
the professional or regulatory groups.196 
The current provider-patient relationship is built on pater-
nalism.197 Moving to a partnership will allow relationships 
built on beneficence rather than rights. Unlike paternalism, 
beneficence is not in conflict with the autonomy called for by 
various bioethics policies.198 In closing, there are a number of 
areas where careful consideration would alleviate some of the 
challenges described above. 
i. Reidentification 
Wolf et al. note three different solutions to alleviate the 
challenges associated with reidentification: (1) primary re-
searchers could reidentify participants when needed; (2) the 
biobank itself could hold the key to reidentification; or (3) they 
could rely on a “trusted intermediary” or “honest broker” to 
hold the key and reidentify.199 It is possible, as is the case for 
                                                 
 196. Dressler, supra note 24, at 96–97. 
 197. Fernandez, supra note 138, at 46–47. 
 198. O’Doherty et al., supra note 174, at 372 (noting that increased 
participation by disease communities actually does not have a negative effect 
on the formation of biobank despite widespread knowledge of related 
concerns). 
 199. Wolf et al., supra note 3, at 375–76. The disclosure process is best 
served if a strategy is decided at the onset of the project instead of when 
problems emerge. Mark A. Rothstein, Tiered Disclosure Options Promote the 
Autonomy and Well-Being of Research Subjects, AM. J. BIOETHICS, Nov.–Dec. 
2006, at 20, 21 (advocating for patients to be given a range of disclosure 
options); Rihab Yassin et al., Custodianship as an Ethical Framework for 
Biospecimen-Based Research, 2010 CANCER EPIDEMIOLOGY BIOMARKERS & 
PREVENTION 1012, 1012 (emphasizing that transparency can possitively affect 
the relationship between researchers and patients). 
009 TERRY_PROOF -SK.DOCX (DO NOT DELETE) 7/5/2012 1:21 PM 
732 MINN. J. L. SCI. & TECH. [Vol. 13:2 
 
 
the Genetic Alliance Registry and BioBank,200 for the biobank 
to be the trusted intermediary.201 There are electronic solutions 
being considered to alleviate the burden and complex challeng-
es of varied preferences in different contexts.202 
ii. Participant-Centricity 
Partnerships between researchers and participants could 
be a core around which robust biomedical research could be de-
veloped, and offering participants the results from research 
could cement that relationship.203 A more participant-centric 
engagement will alleviate some of the tensions and help to de-
fine the solutions that are required.204 
A major attribute of biobanks becoming participant-centric 
is recognition of the context in which people make decisions 
and the dynamic nature of contextual decision-making.205 For 
this reason, biobanks must make it easy for participants to 
modify their preferences.206 Technology solutions can offer flex-
ibility and the opportunity to customize one’s preferences to the 
state of one’s life, including the immediate needs of the partici-
pant and their family.207 
                                                 
 200. About BioBank, GENETIC ALLIANCE REGISTRY & BIOBANK, 
http://www.biobank.org/english/View.asp?x=1360 (last visited Feb. 9, 2012). 
 201. Wolf et al., supra note 3, at 80; see also Jimmie Vaught et al., An NCI 
Perspective on Creating Sustainable Biospecimen Resources, 2011 J. NAT’L 
CANCER INST. MONOGRAPHS 1, 2 (2011) (noting that the National Cancer In-
stitute has identified ethical and legal requirements in addition to other best 
practices). 
 202. Kohane et al., supra note 138, at 836–37. 
 203. See Grégoire Moutel et al., Communication of Pharmacogenetic 
Research Results to HIV-Infected Treated Patients: Standpoints of 
Professionals and Patients, 13 EUR. J. HUM. GENETICS 1055, 1059 (2005) 
(identifying the potential positive effects of informing patients participating in 
long-term studies). 
 204. Id. (noting that withholding information can lead to anxiety). 
 205. See Wolf et al., supra note 3, at 380 (explaining that biobanks could 
participate in the disclosure process). 
 206. Bovenberg, supra note 2, at 234 (explaining that biobanks can ease 
the process by regularing meeting with participants and using the internet to 
communicate changes); see also Knoppers et al., supra note 135, at 1173 
(“[P]ublishing clinical research results in a scientific journal or in a regulatory 
database is no longer ethically sufficient. The ethical principles of respect for 
the person, beneficence and justice obligate the researcher to offer results in a 
manner that is clear and understandable to the research participants.”). 
 207. See Bovenberg, supra note 2, at 234 (noting that the internet can help 
people make changes to disclosures); Kaye, supra note 142. 
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If biobanks were established primarily in the service of 
participants, then decision-making would be easier.208 It might 
also be said that it would be harder to conduct objective re-
search in the service of science—science that will lead to the so-
lutions the participants may desperately need.209 This is proba-
bly true but not a reason to move participant interests to the 
side or to demote them. It is also true that a sophisticated sys-
tem can offer participants the choice to donate their sample to 
be used for any and all research with no strings attached, ex-
pressing no desire for the return of RRs and IFs.210 
iii. Expense/Cost 
There is great concern that there is no reasonable way to 
pay for complex consenting systems that would allow partici-
pant preferences to determine the return of research results 
and incidental findings.211 One need only consider the current 
social network systems, including the inexpensive nature of 
such systems, to imagine comparable systems for the research 
world. Facebook, with a network of around 800 million individ-
uals, representing the third largest country on the planet (only 
smaller than China and India), started on a couple of comput-
ers in a dorm room.212 Craigslist, with more than 20 billion 
page views per month, began as a listserv by Craig Newmark 
when he was new to San Francisco and trying to find events in 
the city.213 Of course, these systems now have whole economies, 
largely based on advertising or subscriptions, connected to 
them to enable the build outs, expansions, and improvements 
we all have come to expect. While there is a great fear of what 
                                                 
 208. See Wolf et al., supra note 3, at 378. 
 209. Landy, supra note 171, at 4–5 (noting that there are problems with 
disease advocacy organizations, the parent groups that run some biobanks); 
see supra Part II.F. (explaining the problem with antiangiogenesis therapies 
on conducting clinical trials for a small disease community). 
 210. See Rothstein, supra note 199, at 21 (advocating a tiered approach 
that lets patients make a choice about disclosure and the length of the term of 
use of genetic samples). 
 211. See Moutel, supra note 203, at 1059. 
 212. See Don Reisinger, Facebook Six Years Later: From a Dorm Room Ex-
periment to a Household Name, L.A. TIMES, Feb. 4, 2010, 
http://latimesblogs.latimes.com/technology/2010/02/facebook-six-years-later-
from-a-dorm-room-to-a-household-name.html. 
 213. See On the Record: Craig Newmark, S.F. CHRON. (Aug. 15, 2004), 
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/08/15/NEWMARK.TMP 
&ao=all. 
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advertising might do to biobanking, clinical trials, and biomedi-
cal research in general, it is possible to maintain authentic and 
transparent systems without endangering the core mission.214 
The public can distinguish to some extent between authentic 
and inauthentic network tools.215 In addition, because most of 
these interactions are virtual, new tools will be needed to sup-
plement the ones people already use to discover inauthenticity. 
Currently, there are researchers working on algorithms to de-
tect fake reviews; for example, a team at Cornell has published 
a possible method for such screenings.216 
It is possible that the costs for creating and maintaining 
systems that allow individuals to detail how and when they 
want results to be reported back to them can be built into 
grants.217 It is also a certainty that the cost of such systems will 
decrease over time.218 In an analogous information technology 
example, when I built a shopping cart to take donations on the 
PXE International website in 1997, it cost me hundreds of 
hours of coding work. Now I can add a robust shopping cart 
free, with no design, build, installation, or transaction fees. 
This was unthinkable a few years ago. A whole ecosystem has 
been built around these tools, and the tools themselves cost 
very little to nothing now. The same can happen with emerging 
software such as Private Access;219 Bio-PIN;220 an ‘intelligent’ 
                                                 
 214. Rothstein, supra note 199, at 21. 
 215. Cf. Moutel, supra note 203, at 1059 (noting that patients wanted to 
view results even if they did not have the technical science background to ac-
curately interpret the results). 
 216. Myle Ott et al., Finding Deceptive Opinion Spam by Any Stretch of the 
Imagination, in PROCEEDINGS OF THE 49TH ANNUAL MEETING OF THE 
ASSOCIATION FOR COMPUTATIONAL LINGUISTICS: HUMAN LANGUAGE 
TECHNOLOGIES 309, 309 (2011) (researching filtering of opinion spam for 
websites such as Yelp and TripAdvisor). 
 217. Fernandez, supra note 138, at 48. 
 218. See William E. Evans & Mary V. Relling, Moving Toward Individual-
ized Medicine with Pharmacogenomics, 429 NATURE 464, 468 (2004) 
(“[A]dvances in technology will drive down the cost of genotyping sooner than 
science and medicine will be able to establish definitive polygenic models for 
optimizing drug therapy.”). 
 219. About Us, PRIVATE ACCESS, INC., 
https://www.privateaccess.info/about-us/ (last visited Feb. 9, 2011) (“Private 
Access, Inc. has developed a transformative consumer-centric technology 
platform that permits internet search for private information.”). 
 220. J.J. Nietfeld et al., The Bio-PIN: A Concept to Improve Biobanking, 11 
NATURE REVS. CANCER 303, 304 (2011) (“The Bio-PIN concept is based on the 
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cancer risk protocol;221 the UK BioBank,222 which considers 
consent as an ongoing process; and others. As Fullerton et al. 
put it: “It is time to acknowledge that first-generation technical 
and regulatory solutions are not up to the task of addressing 
the ethical and scientific challenges of next-generation 
biorepository research.”223 
B. THE MOVEMENT TOWARD OPEN DATA SHARING 
Some have called for a new ethical framework on collective 
values.224 There is a broad movement towards data sharing 
that is changing our values. The current biomedical research 
culture was built on a 19th century model of win, lose, and 
completion.225 As this culture evolves, impacted by the current 
cultural mores of open access and data sharing, it will enable 
relational, partnership-based, solutions. Until it evolves (and it 
may do so kicking and screaming in some quarters), there will 
be some enormous tensions in the system. At the same time, as 
some suggest, academic medical centers can take a lead in this 
regard.226 It is critical that all of the stakeholders are engaged 
in this culture shift.227 Participants must take a proactive role 
in partnering, with all of the inherent and concurrent responsi-
bilities and benefits. The tension in the system is a beacon of 
light that allows great clarity if all stakeholders are empowered 
to look carefully at the land between policy and practice in re-
turning results. This tension can spur innovation if all stake-
holders work for the benefit of the ultimate goal: better health. 
There will be risks for all entities involved, but the benefits will 
                                                 
principle that from each individual a unique distinguishing biological 
characteristic (DBC) can be derived that is present in every sample of 
biological material from that individual.”); J.J. Nietfeld et al., The Flexibility of 
Biobanking with the Bio-PIN System, 11 NATURE REVS. CANCER 895, 895 
(2011) (“The Bio-PIN system is flexible. It enables donors and biobanks to 
communicate in a secure way . . . .”). 
 221. See J. Scott Roberts et al., Returning Individual Research Rresults: 
Development of a Cancer Genetics Education and Risk Communication 
Protocol, 5 J. EMPIRICAL RES. ON HUM. RES. ETHICS, Sept. 2011, at 17, 23. 
 222. See Tutton & Prainsack, supra note 42, at 1082–83. 
 223. Fullerton et al., supra note 128, at 3. 
 224. Bartha Maria Knoppers & Ruth Chadwick, Human Genetic Research: 
Emerging Trends in Ethics, 6 NATURE REVS. GENETICS 75, 79 (2005). 
 225. See Terry & Terry, supra note 1, at 1–2. 
 226. Heather A. Piwowar et al., Towards a Data Sharing Culture: 
Recommendations for Leadership from Academic Health Centers, 5 PLOS 
MED. 1315, 1315 (2008). 
 227. See id. 
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exceed the risk. The real risk in not creating a dynamic, partic-
ipant-centric system is too great—translation science and those 
awaiting diagnostics and treatments cannot afford that loss. 
 
